Actinium Pharmaceuticals, Inc.
ATNM
$8.84
-$0.12-1.34%
| Weiss Ratings | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.50 | |||
| Price History | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.00% | |||
| 30-Day Total Return | 6.38% | |||
| 60-Day Total Return | 23.98% | |||
| 90-Day Total Return | 37.53% | |||
| Year to Date Total Return | 25.38% | |||
| 1-Year Total Return | -24.20% | |||
| 2-Year Total Return | 6.21% | |||
| 3-Year Total Return | -15.14% | |||
| 5-Year Total Return | -23.99% | |||
| 52-Week High % Change | -33.47% | |||
| 52-Week Low % Change | 64.00% | |||
| Price | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.86 | |||
| 52-Week Low Price | $4.00 | |||
| 52-Week Low Price (Date) | Nov 28, 2023 | |||
| 52-Week High Price (Date) | Mar 22, 2024 | |||
| Valuation | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 201.37M | |||
| Enterprise Value | 126.80M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.84 | |||
| Earnings Per Share Growth | 35.21% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2,362.07 | |||
| Price/Book (Q) | 5.20 | |||
| Enterprise Value/Revenue (TTM) | 1,460.20 | |||
| Price | $6.67 | |||
| Enterprise Value/EBITDA (TTM) | -2.31 | |||
| Enterprise Value/EBIT | -2.28 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 27.43M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 677 3870 | |||
| Address | 100 Park Avenue New York, NY 10017 | |||
| Website | www.actiniumpharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -64,098.76% | |||
| Profit Margin | -60,269.13% | |||
| Management Effectiveness | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -33.17% | |||
| Return on Equity | -- | |||
| Income Statement | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | 81.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 81.00K | |||
| EBITDA (TTM) | -51.28M | |||
| EBIT (TTM) | -51.92M | |||
| Net Income (TTM) | -48.82M | |||
| Net Income Avl. to Common (TTM) | -48.82M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 12.43% | |||
| EPS Diluted (TTM) | -1.84 | |||
| EPS Diluted Growth (Q YOY) | 19.38% | |||
| Balance Sheet | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 76.68M | |||
| Cash Per Share (Q) | $2.80 | |||
| Total Current Assets (Q) | 78.26M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 36.38M | |||
| Current Ratio (Q) | 9.214 | |||
| Book Value Per Share (Q) | $1.32 | |||
| Total Assets (Q) | 81.45M | |||
| Total Current Liabilities (Q) | 8.49M | |||
| Total Debt (Q) | 2.11M | |||
| Total Liabilities (Q) | 45.07M | |||
| Total Common Equity (Q) | 36.38M | |||
| Cash Flow | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -153.00K | |||
| Cash from Financing (TTM) | 14.87M | |||
| Net Change in Cash (TTM) | -32.62M | |||
| Levered Free Cash Flow (TTM) | -31.62M | |||
| Cash from Operations (TTM) | -47.34M | |||
